Literature DB >> 9668343

Sphingolipids as receptor modulators. An overview.

A J Yates1, A Rampersaud.   

Abstract

Glycosphingolipids are amphipathic compounds that exist mainly in the plasmalemma with their oligosaccharide portion protruding into the extracellular environment. In this position they are admirably situated for interacting with both ligands and receptors. Binding studies have demonstrated that specific glycolipids function as receptors for some microorganisms and bacterial toxins. Specific oligosaccharides on both glycolipids and glycoproteins bind members of the selection families, and some gangliosides facilitate integrins binding to their ligands. Gangliosides modulate the trophic factor-stimulated dimerization, tyrosine phosphorylation, and subsequent signal transduction events of several tyrosine kinase receptors. GM3 inhibits both the epidermal growth factor receptor and basic fibroblast factor receptor; several gangliosides except GM3 inhibit the platelet-derived growth-factor receptor; GM1 enhances nerve growth-factor-stimulated activation of TrkA; insulin receptor is inhibited to varying degrees by several gangliosides, but 2-->3 sialosylparagloboside is most effective. Activities of the beta(1)-adrenergic and delta-opioid receptors are modulated by GM1. Available information suggests that glycolipids serve as coordinators of multiple receptor functions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9668343     DOI: 10.1111/j.1749-6632.1998.tb09662.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  17 in total

Review 1.  Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction.

Authors:  Jaap J Plomp; Hugh J Willison
Journal:  J Physiol       Date:  2009-06-29       Impact factor: 5.182

2.  Combinatorial PCR approach to homology-based cloning: cloning and expression of mouse and human GM3-synthase.

Authors:  D Kapitonov; E Bieberich; R K Yu
Journal:  Glycoconj J       Date:  1999-07       Impact factor: 2.916

3.  Sex- and age-related differences in ceramide dihexosides of primary human brain tumors.

Authors:  A J Yates; T K Franklin; B W Scheithauer; P C Burger; D K Pearl
Journal:  Lipids       Date:  1999-01       Impact factor: 1.880

4.  Involvement of beta1-integrin up-regulation in basic fibroblast growth factor- and epidermal growth factor-induced proliferation of mouse neuroepithelial cells.

Authors:  Yusuke Suzuki; Makoto Yanagisawa; Hirokazu Yagi; Yoshihiko Nakatani; Robert K Yu
Journal:  J Biol Chem       Date:  2010-04-06       Impact factor: 5.157

5.  Gangliosides inhibit the development from monocytes to dendritic cells.

Authors:  M Wölfl; W Y Batten; C Posovszky; H Bernhard; F Berthold
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 6.  Disialyl gangliosides enhance tumor phenotypes with differential modalities.

Authors:  Koichi Furukawa; Kazunori Hamamura; Yuki Ohkawa; Yuhsuke Ohmi; Keiko Furukawa
Journal:  Glycoconj J       Date:  2012-07-05       Impact factor: 2.916

Review 7.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

8.  Ganglioside GM3 Is Antiangiogenic in Malignant Brain Cancer.

Authors:  Thomas N Seyfried; Purna Mukherjee
Journal:  J Oncol       Date:  2010-06-20       Impact factor: 4.375

9.  Synaptic function of cholinergic-specific Chol-1alpha ganglioside.

Authors:  Susumu Ando; Yasukazu Tanaka; Satoru Kobayashi; Fumiko Fukui; Machiko Iwamoto; Hatsue Waki; Tadashi Tai; Yoshio Hirabayashi
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

10.  Lyso-GM3, its dimer, and multimer: their synthesis, and their effect on epidermal growth factor-induced receptor tyrosine kinase.

Authors:  Yoshimi Murozuka; Naoko Watanabe; Kenichi Hatanaka; Sen-itiroh Hakomori
Journal:  Glycoconj J       Date:  2007-07-19       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.